PepGen Inc, a developer of oligonucleotide therapies for neuromuscular and neurologic diseases, has raised $112.5 million in financing. The investors included RA Capital Management, Oxford Sciences Innovation and CureDuchenne Ventures.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: